Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients

被引:14
|
作者
Lindenmayer, JP
Adityanjee
VitalHerne, M
Bark, N
Grochowski, S
Moynihan, N
机构
[1] VET ADM MED CTR,SCHIZOPHRENIA PROGRAM,DAYTON,OH
[2] ALBERT EINSTEIN COLL MED,BRONX PSYCHIAT CTR,SCHIZOPHRENIA RES UNIT,BRONX,NY 10467
关键词
metachlorophenylpiperazine; schizophrenia; clozapine; cortisol response; treatment refractory; serotonin;
D O I
10.1016/S0006-3223(96)00296-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Oral metachlorophenylpiperazine (m-CPP) as a direct-acting postsynaptic serotonergic agonist was used to study serotonergic dysfunction in treatment-refractory chronic schizophrenia based on the hypothesis that some patients may show central serotonergic hypersensitivity, Seventeen DSM-III-R chronic schizophrenic patients with a history of neuroleptic nonresponse underwent double-blind challenge with oral m-CPP (0.25 mg/kg body weight) and placebo after medication washout, m-CPP significantly elevated both prolactin and cortisol levels as compared to placebo. There was a significant relationship between change in cortisol level and change in psychopathology under m-CPP; a blunted cortisol response was associated with a decrease in total psychopatholoy, while an increase in cortisol response related to an increase in psychopathology. Similarly, decrease in severity of the activation factor and the hostility factor was associated with a smaller cortisol response in the m-CPP condition. These results point to heterogeneity in central serotonergic sensitivity within the context of different subpopulations of serotonergic receptors. (C) 1997 Society of Biological Psychiatry.
引用
收藏
页码:6 / 12
页数:7
相关论文
共 50 条
  • [1] Treatment-refractory schizophrenia
    Buckley, PF
    Shendarkar, N
    CURRENT OPINION IN PSYCHIATRY, 2005, 18 (02) : 165 - 173
  • [2] DOES ELECTROCONVULSIVE THERAPY CHANGE THE RESPONSE TO PHARMACOLOGICAL TREATMENT IN PATIENTS WITH TREATMENT-REFRACTORY SCHIZOPHRENIA?
    Hirota, T.
    Kanazawa, K.
    Takenaka, H.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [3] Risperidone in treatment-refractory schizophrenia
    Wirshing, DA
    Marshall, BD
    Green, MF
    Mintz, J
    Marder, SR
    Wirshing, WC
    AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (09): : 1374 - 1379
  • [4] Pharmacotherapy for treatment-refractory schizophrenia
    Van Sant, Scott P.
    Buckley, Peter F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (03) : 411 - 434
  • [5] Algorithm for treatment-refractory schizophrenia
    Koshino, Y
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 1999, 53 : S9 - S13
  • [6] Aripiprazole in Treatment-Refractory Schizophrenia
    Hsu, Wen-Yu
    Lee, Chien-I
    Chiu, Nan-Ying
    Kahn, David A.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2009, 15 (03) : 221 - 226
  • [7] THE PHARMACOEPIDEMIOLOGY OF TREATMENT-REFRACTORY SCHIZOPHRENIA
    COLLINS, EJ
    HOGAN, TP
    AWAD, AG
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1992, 37 (03): : 192 - 195
  • [8] RISPERIDONE FOR TREATMENT-REFRACTORY SCHIZOPHRENIA
    TANNER, TB
    GANGULI, R
    REDDY, R
    ALLEN, M
    FIELD, K
    AMERICAN JOURNAL OF PSYCHIATRY, 1995, 152 (08): : 1233 - 1233
  • [9] Treatment-refractory schizophrenia.
    Buckley P.F.
    Wiggins L.D.
    Sebastian S.
    Singer B.
    Current Psychiatry Reports, 2001, 3 (5) : 393 - 400
  • [10] Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia
    Mossaheb, N.
    Sacher, J.
    Wiesegger, G.
    Klein, N.
    Spindelegger, C. J.
    Asenbaum, S.
    Dudczak, R.
    Kasper, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S416 - S416